文献速递淋巴瘤

PET与ctDNA联合应答预测滤泡性淋巴瘤一线诱导治疗后POD24

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.
PubMed 文献 · Blood · 2025-01-01

研究基于RELEVANCE 3期试验中141例具备随机化和诱导结束(第24周)时血清ctDNA检测与PET图像的滤泡性淋巴瘤患者。12%发生POD24。诱导结束时ctDNA未检出者中位PFS未达到,ctDNA阳性者为17.7个月(95%CI 1.4至未达到,P=0.0038);PET未检出者中位PFS未达到,PET阳性者为28.3个月(95%CI 2.9至未达到,P=0.0002)。两项检测对POD24的阴性预测值均>90%,联合后阳性预测值升至85.7%。

要点

  • 诱导结束时ctDNA未检出者中位PFS未达到,ctDNA阳性者17.7个月(P=0.0038)。
  • 诱导结束时PET未检出者中位PFS未达到,PET阳性者28.3个月(P=0.0002)。
  • ctDNA与PET对POD24的阴性预测值均>90%,联合后阳性预测值85.7%。

核心结论

  • 诱导结束时PET应答与ctDNA MRD联合可早期预测POD24,可能有助于提前做出治疗决策。

研究设计与样本

  • RELEVANCE 3期试验(NCT01650701)中141例代表性队列,均具备随机化和诱导结束(第24周)时血清ctDNA检测样本与PET图像。
  • ctDNA采用定制130千碱基捕获panel分析,其中相位变异(PV)富集区域占panel的39%。

主要发现

  • 12%的患者发生POD24。
  • 基线时140例(99.3%)检出ctDNA;124例(88%)检出PV,诱导结束时ctDNA MRD评估仅考虑PV以优化特异性。
  • 诱导结束时ctDNA未检出的112例中位PFS未达到,ctDNA阳性者中位PFS为17.7个月(95%CI 1.4至未达到,P=0.0038)。
  • 诱导结束时PET未检出的104例中位PFS未达到,PET阳性者中位PFS为28.3个月(95%CI 2.9至未达到,P=0.0002)。
  • ctDNA MRD与PET对POD24的阴性预测值均>90%;阳性预测值ctDNA MRD为58.3%、PET为45%,两者联合升至85.7%且阴性预测值不变。

临床怎么用

  • 原文结论认为诱导结束时PET应答与ctDNA MRD联合可早期预测POD24,可能有助于提前做出治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with follicular lymphoma who experience disease progression within 24 months of diagnosis (POD24) have a lower survival. Positron emission tomography (PET) response and circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at end of induction (EOI) may allow their early identification. A representative cohort of 141 patients from the RELEVANCE phase 3 trial with both available serum samples for ctDNA testing and PET images at randomization and at EOI (week 24) was investigated. Twelve percent were POD24. ctDNA was analyzed using a customized 130-kilobase capture panel, with phased variant (PV) enriched regions representing 39% of the panel. ctDNA was detected in 140 patients (99.3%) at baseline. To optimize specificity, only PVs, found in 124 patients (88%), were considered for ctDNA MRD assessment at EOI. Median progression-free survival (PFS) from EOI was not reached (NR) for the 112 patients with undetected ctDNA at EOI vs 17.7 months (95% confidence interval [CI], 1.4 to NR) for patients with positive ctDNA (MRD+) (P = .0038). Similarly, median PFS was NR for the 104 patients with undetected disease on PET at EOI vs 28.3 months (95% CI, 2.9 to NR; P = .0002) for patients with PET positivity. Both tests had a negative predictive value (NPV) of >90% for POD24. The positive predictive value was 58.3% for ctDNA MRD and 45% for PET but increased to 85.7% when both parameters were combined, without alteration of NPV. These data show that the combination of PET response and ctDNA MRD at EOI allows an early prediction of POD24, which may lead to a preemptive treatment decision. This trial was registered at www.clinicaltrials.gov as #NCT01650701.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Claudel A, Cottereau AS, Bachy E, et al. Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment. Blood. 2025. PMID: 40499012. doi:10.1182/blood.2024027727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。